SOMERVILLE, Mass.– bluebird bio, Inc. has rebranded as Genetix Biotherapeutics Inc., marking a return to the company’s original name and mission. The transition follows new ownership, a strengthened financial foundation, and the appointment of a leadership team led by CEO David Meek.
Genetix enters this new era with three FDA-approved one-time gene therapies for sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy. These treatments address the root causes of disease and are designed to deliver lasting clinical benefits.
The rebrand also reflects a sharpened focus on commercial execution, scaling patient access, and improving the treatment experience for patients and providers. “Our rebrand is far more than a name change—it represents renewed hope for thousands of individuals who could benefit from our genetic therapies,” said Meek. “Although we are the market leader, the vast majority of patients have not yet received treatment. Fortunately, our therapies are a one-time administered, durable treatment, which can dramatically improve clinical manifestations. Our sole purpose is to work with patients, providers, and payers to make access simpler and more streamlined. We’ve assembled an experienced team of industry leaders and have outlined a clear plan to do just that, and I am confident we will execute successfully.”
Founded in 1992 as Genetix Pharmaceuticals, the company established an early scientific foundation through pioneering research and proof-of-concept trials. It became bluebird bio in 2010 and went on to become the first and only company to secure FDA approval for three gene therapies. In June 2025, bluebird announced its sale to new investors and transition to private ownership, paving the way for the rebrand and renewed focus.
The company said its near-term priorities include expanding its network of Qualified Treatment Centers to improve patient access, substantially increasing manufacturing capacity within the next year, and investing in capabilities such as cryopreservation of patient stem cells to enhance the treatment process. Genetix also continues development of lovo-cel (lovotibeglogene autotemcel), a Phase 3 clinical program for sickle cell disease that is fully enrolled and ongoing.
“Today we are honoring decades of scientific innovation while sharpening our focus on what matters most: ensuring more patients can benefit from our therapies,” Meek said. (Source: IANS)
